EXPERIMENTAL STUDY OF ANTIVIRAL ACTIVITY OF SPORE-FORMING BACTERIUM BACILLUS PUMILUS «PASHKOV»


Cite item

Full Text

Abstract

Aim. To study antiviral activity of metabolites of spore-forming strain «Pashkov» of B.pumilus on the model of enterovirus infection in vitro. Materials and methods. B.pumilus strain «Pashkov» isolated from environment and identified by common methods. Cell cultures: Vero-6, Vero-ECC, and Vero-E6. Enteroviruses: type 1 poliovirus, Coxsackie B virus (1—6), ECHO-3, and ECHO-6 viruses. Unfectious activity of viruses was evaluated according to their cytopathogenic effect on Vero-E6 cell line by method of serial dilutions. Cultural fluid (CF) for the study was obtained by centrifugation and sterilizing filtration of B.pumilus strain «Pashkov» biomass produced by cultivation during 72 hours on optimized nutrient medium. Cytotoxicity of CF (chronic and acute) and maximal tolerated dose were measured by effect on viability of Vero-E6 cells, which was assessed by trypan blue exclusion test of cell viability. For measurement of antiviral activity (AV-activity), two treatment schedules — therapeutic and prophylactic — were used. Results. The most sensitive cell lines were Vero-ECC and Vero-E6. Assessment of AV-activity showed that protective effect was observed for all dilutions of CF and lasted for 7 days from time of infection by used doses of virus. CF does not have acute and chronic cytotoxicity. CF studied in vitro with Vero-E6 cells infected with 4 types of enteroviruses provided protection against viruses and had prophylactic effect. Degree of effect of CF depended from type of enterovirus, dose used and CF dilution. Conclusion. For the first time effective antiviral activity of CF, which have low cytotoxicity for Vero-E6 cell culture in vitro and is produced by strain «Pashkov» of B.pumilus , was demonstrated. Obtained data open perspectives for development of medications against enterovirus infections.

Full Text

ЭКСПЕРИМЕНТАЛЬНОЕ ИЗУЧЕНИЕ ПРОТИВОВИРУСНОЙ АКТИВНОСТИ СПОРООБРАЗУЮЩИХ БАКТЕРИЙ BACILLUS PUMILUS «ПАШКОВ»
×

About the authors

N. A Mikhaylova

Sechenov Moscow Medical Academy; Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

F. G Nagieva

Sechenov Moscow Medical Academy; Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

O. M Grinko

Sechenov Moscow Medical Academy; Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

V. V Zverev

Sechenov Moscow Medical Academy; Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

References

  1. Ворошилова М.К. Энтеровирусные инфекции человека. М., Медицина, 1979.
  2. Лашкевич В.А. 100 лет изучения вируса полиомиелита и неполиомиелитных энтеровирусов. Вопр. вирусол. 2008, 4: 41-44.
  3. Лукманова К.А., Гизатуллина С.В., Магазов Р.Ш. и др. Антагонистическая активность бактерий рода Bacillus в отношении грибов дерматофитов. Журн. микробиол. 2008, 4: 21-23.
  4. Носов С.Д. Энтеровирусные (Коксаки и ECHO) инфекции. Руководство по инфекционным болезням у детей. С.Д. Носов (ред.). М., Медицина, 1972.
  5. Осипова И.Г., Михайлова Н.А., Сорокулова И.Б. и др. Споровые пробиотики. Журн. микробиол. 2003, 3: 113-117.
  6. Орлова М.В., Смирнова Т.А., Шамшина Т.Н. и др. Антибактериальная активность Bacillus latesporus. Биотехнология. 1995, 1—2: 23-26.
  7. Смирнов В.В., Резник С.Р., Сорокулова И.Б. Методические рекомендации по выделению и идентификации бактерий рода Bacillus из организма человека и животных. Киев, 1983.
  8. Bottone E.G., Peluso R.W. Production by Bacillus pumilus (MSH) of an antifungal compound that is active against Mucoraceae and Aspergillus species: preliminary report. J. Med. Microbiol. 2003, 52: 69-74.
  9. Dirk Vollenbroich, Muhsin Ozel, Joachim Vater et al. Mechanism of inactivation of enveloped viruses by the biosurfactant from Bacillus subtilis. Biologicals. 1997, 23 (5): 289-297.
  10. Kinchington D., Kangro H., Jeffries D.J. Design and testing of antiviral compounds. In: Medical Virology: a practical approach. 1995, р. 147-171.
  11. Muscettola M., Grasso G., Blach-Olszewska Z. et al. Effect of Bacillus subtilis spores on interferon production. Pharmacol. Res. 1992, 26 (2): 176-177.
  12. Taraoka S. Bacillus natto culture extract/Pat.US 6,730 504 B2/Date of patent: May 4, 2004. Assignee: Japan Bio Science Laboratory Co., Ltd., Osaka (JP).
  13. Yeh M.-S., Wei Y.-H., Wei Y.-H., Chang J.-S. Enhanced production of surfactin from Bacillus subtilis by addition of solid carries. Biotehnol. Progr. 2005, 21 (4): 1329-1334.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2010 Mikhaylova N.A., Nagieva F.G., Grinko O.M., Zverev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies